Index - P/E - EPS (ttm) - Insider Own 23.85% Shs Outstand 34.17M Perf Week -0.99%
Market Cap 857.17M Forward P/E - EPS next Y - Insider Trans 44.62% Shs Float 27.28M Perf Month -
Income - PEG - EPS next Q -0.70 Inst Own 14.01% Short Float 0.70% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans - Short Ratio 0.28 Perf Half Y -
Book/sh -5.77 P/B - EPS next Y - ROA - Short Interest 0.19M Perf Year -
Cash/sh 4.44 P/C 5.39 EPS next 5Y - ROE - 52W Range 18.30 - 26.62 Perf YTD 30.69%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -10.11% Beta -
Dividend TTM - Quick Ratio 12.61 Sales past 5Y 0.00% Gross Margin - 52W Low 30.77% ATR (14) 2.18
Dividend Ex-Date - Current Ratio 12.61 EPS Y/Y TTM - Oper. Margin - RSI (14) - Volatility 9.51% -
Employees - Debt/Eq 0.08 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 42.33
Option/Short No / Yes LT Debt/Eq 0.04 EPS Q/Q - Payout - Rel Volume 0.38 Prev Close 23.75
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings Aug 28 Avg Volume 693.69K Price 23.93
SMA20 8.09% SMA50 8.09% SMA200 8.09% Trades
Volume 46,277 Change 0.76%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-21-24 Initiated Morgan Stanley
Overweight
$40
Oct-21-24 Initiated Jefferies
Buy
$42
Oct-21-24 Initiated Citigroup
Buy
$45
Oct-21-24 10:53AM
Oct-17-24 09:45AM
Oct-12-24 02:31PM
Oct-07-24 09:10PM
Oct-05-24 07:15AM
09:05AM
Loading…
Oct-03-24 09:05AM
Oct-01-24 04:30PM
Sep-26-24 04:08PM
(Investor's Business Daily)
02:36PM
08:25AM
Sep-25-24 08:00PM
04:13PM
11:27AM
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Richmond, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pande Vijay Satyanand Director Oct 01 '24 Buy 19.73 126,793 2,501,626 1,026,793 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 02 '24 Buy 19.73 67,096 1,323,804 1,093,889 Oct 03 07:19 PM Pande Vijay Satyanand Director Oct 03 '24 Buy 19.90 25,306 503,589 1,119,195 Oct 03 07:19 PM Cormorant Asset Management, LP Former 10% Owner Sep 27 '24 Buy 18.00 450,000 8,100,000 1,629,529 Oct 01 04:01 PM Pande Vijay Satyanand Director Sep 27 '24 Buy 18.00 900,000 16,200,000 900,000 Sep 27 04:28 PM ENRIGHT PATRICK G Director Sep 27 '24 Buy 18.00 400,000 7,200,000 1,710,589 Sep 27 04:26 PM HEALY JAMES Director Sep 27 '24 Buy 18.00 666,665 11,999,970 2,227,124 Sep 27 04:22 PM
Index - P/E - EPS (ttm) - Insider Own - Shs Outstand 38.32M Perf Week 20.35%
Market Cap 933.36M Forward P/E - EPS next Y - Insider Trans - Shs Float 20.23M Perf Month 21.98%
Income - PEG - EPS next Q -7.23 Inst Own 10.05% Short Float 1.14% Perf Quarter -
Sales - P/S - EPS this Y - Inst Trans 179.72% Short Ratio 1.08 Perf Half Y -
Book/sh -7.54 P/B - EPS next Y - ROA - Short Interest 0.23M Perf Year -
Cash/sh 4.62 P/C 5.07 EPS next 5Y - ROE - 52W Range 16.17 - 26.11 Perf YTD 29.24%
Dividend Est. - P/FCF - EPS past 5Y - ROI - 52W High -10.16% Beta -
Dividend TTM - Quick Ratio 4.82 Sales past 5Y - Gross Margin - 52W Low 45.07% ATR (14) 2.04
Dividend Ex-Date Dec 24, 2019 Current Ratio 4.82 EPS Y/Y TTM - Oper. Margin - RSI (14) 65.07 Volatility 12.10% 11.21%
Employees - Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 36.75
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q - Payout - Rel Volume 1.55 Prev Close 25.68
Sales Surprise - EPS Surprise - Sales Q/Q - Earnings Aug 28 Avg Volume 214.37K Price 23.46
SMA20 21.68% SMA50 23.69% SMA200 23.69% Trades
Volume 58,070 Change -8.66%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-08-24 Initiated Morgan Stanley
Overweight
$40
Oct-08-24 Initiated Jefferies
Buy
$35
Oct-08-24 Initiated Guggenheim
Buy
$45
Oct-08-24 Initiated Citigroup
Buy
$27
Oct-14-24 06:45AM
Sep-19-24 04:15PM
Sep-13-24 04:09PM
12:19AM
Sep-12-24 10:37PM
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MOULDER LEON O JR Chief Executive Officer Sep 18 '24 Buy 17.91 10,000 179,100 1,662,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 20 '24 Buy 18.45 5,000 92,270 1,672,039 Sep 20 06:34 PM MOULDER LEON O JR Chief Executive Officer Sep 19 '24 Buy 17.89 5,000 89,450 1,667,039 Sep 20 06:34 PM Enavate Sciences GP, LLC 10% Owner Sep 16 '24 Buy 17.00 882,353 15,000,001 3,761,359 Sep 18 04:15 PM Lu Hongbo Director Sep 13 '24 Buy 17.00 58,823 999,991 58,823 Sep 17 07:52 PM ENRIGHT PATRICK G Director Sep 16 '24 Buy 17.00 440,000 7,480,000 774,530 Sep 16 08:57 PM Nunn Jason Raleigh Director Sep 16 '24 Buy 17.00 882,352 14,999,984 1,946,564 Sep 16 08:54 PM Fairmount Funds Management LLC Director Sep 16 '24 Buy 17.00 300,000 5,100,000 1,604,891 Sep 16 08:54 PM SR ONE CAPITAL MANAGEMENT, LLC 10% Owner Sep 16 '24 Buy 17.00 2,235,294 37,999,998 1,946,564 Sep 16 08:51 PM
Index - P/E 19.97 EPS (ttm) 5.60 Insider Own 3.45% Shs Outstand 62.26M Perf Week -3.31%
Market Cap 6.90B Forward P/E 5.20 EPS next Y 21.49 Insider Trans -0.31% Shs Float 59.62M Perf Month 2.51%
Income 394.92M PEG 1.60 EPS next Q 5.51 Inst Own 95.60% Short Float 5.66% Perf Quarter 2.08%
Sales 3.91B P/S 1.77 EPS this Y 6.75% Inst Trans -2.09% Short Ratio 4.99 Perf Half Y 3.23%
Book/sh 60.94 P/B 1.83 EPS next Y 10.08% ROA 3.49% Short Interest 3.38M Perf Year -13.04%
Cash/sh 32.08 P/C 3.49 EPS next 5Y 12.49% ROE 10.84% 52W Range 99.06 - 134.48 Perf YTD -9.09%
Dividend Est. - P/FCF 6.61 EPS past 5Y -3.53% ROI 4.42% 52W High -16.85% Beta 0.57
Dividend TTM - Quick Ratio 1.90 Sales past 5Y 15.52% Gross Margin 73.60% 52W Low 12.88% ATR (14) 2.43
Dividend Ex-Date - Current Ratio 2.25 EPS Y/Y TTM 546.69% Oper. Margin 16.63% RSI (14) 51.39 Volatility 1.85% 2.22%
Employees 2800 Debt/Eq 1.54 Sales Y/Y TTM 3.91% Profit Margin 10.10% Recom 1.50 Target Price 175.72
Option/Short Yes / Yes LT Debt/Eq 1.37 EPS Q/Q 70.48% Payout 0.00% Rel Volume 0.29 Prev Close 113.10
Sales Surprise 1.37% EPS Surprise 7.68% Sales Q/Q 6.95% Earnings Jul 31 AMC Avg Volume 676.89K Price 111.82
SMA20 0.69% SMA50 0.81% SMA200 -1.35% Trades
Volume 33,667 Change -1.13%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-24 Initiated Goldman
Buy
$169
Jan-03-24 Initiated Robert W. Baird
Outperform
$160
Nov-27-23 Downgrade UBS
Buy → Neutral
$170 → $135
Sep-29-23 Initiated Raymond James
Mkt Perform
Jun-12-23 Resumed Wells Fargo
Equal Weight
$184 → $140
Dec-09-22 Upgrade Goldman
Neutral → Buy
$192 → $190
Jun-14-22 Initiated UBS
Buy
$194
Apr-06-22 Downgrade Goldman
Buy → Neutral
$202 → $196
Nov-19-21 Resumed Goldman
Buy
$198
Oct-07-21 Resumed Jefferies
Buy
$172
Oct-05-21 Initiated Citigroup
Buy
$200
Sep-23-21 Initiated Needham
Buy
$220
May-19-21 Resumed JP Morgan
Overweight
$183 → $206
Apr-07-21 Resumed RBC Capital Mkts
Outperform
$186
Feb-05-21 Reiterated H.C. Wainwright
Buy
$195 → $207
Feb-03-21 Upgrade Piper Sandler
Neutral → Overweight
$150 → $175
Jan-29-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
Dec-16-20 Initiated UBS
Buy
$174
Nov-03-20 Reiterated H.C. Wainwright
Buy
$185 → $195
Oct-09-20 Reiterated H.C. Wainwright
Buy
$175 → $185
Show Previous Ratings
Oct-18-24 04:34PM
(Pharmaceutical Technology)
05:21AM
Oct-17-24 09:55AM
09:40AM
Oct-16-24 03:55PM
08:54AM
Loading…
08:54AM
07:35AM
Oct-15-24 11:50AM
10:31AM
07:30AM
06:47AM
Oct-14-24 09:52AM
Oct-11-24 12:32PM
Oct-09-24 04:15PM
Oct-08-24 04:22AM
10:00AM
Loading…
Oct-04-24 10:00AM
Oct-03-24 07:40AM
Oct-01-24 09:40AM
Sep-16-24 07:30AM
Sep-09-24 07:58AM
Sep-07-24 10:17PM
Sep-05-24 07:30AM
01:07AM
Sep-04-24 12:12AM
Sep-03-24 07:00AM
Sep-02-24 06:05PM
Aug-30-24 11:31AM
01:16AM
Aug-23-24 10:13AM
(Pharmaceutical Technology)
Aug-22-24 04:05PM
04:15PM
Loading…
Aug-21-24 04:15PM
Aug-06-24 09:55AM
09:40AM
Aug-05-24 04:06PM
09:15AM
Jul-31-24 10:36PM
05:45PM
04:40PM
(Associated Press Finance)
04:05PM
Jul-29-24 06:00AM
Jul-25-24 04:05PM
Jul-24-24 10:01AM
Jul-23-24 03:52AM
Jul-22-24 07:45AM
Jul-19-24 01:58PM
Jul-17-24 04:15PM
Jul-11-24 08:30AM
Jul-09-24 07:45AM
Jul-04-24 08:09AM
Jul-01-24 12:16AM
Jun-26-24 02:11PM
Jun-25-24 03:39PM
Jun-21-24 07:00AM
06:33AM
Jun-20-24 04:08PM
(Investor's Business Daily)
10:08AM
(Investor's Business Daily)
07:45AM
Jun-14-24 06:13AM
Jun-11-24 10:42AM
Jun-03-24 02:27PM
Jun-01-24 08:05AM
May-31-24 11:31AM
May-30-24 07:30AM
May-29-24 04:15PM
07:45AM
May-28-24 07:00AM
May-26-24 10:09AM
May-23-24 06:00AM
May-22-24 07:01PM
04:00PM
May-17-24 02:32PM
May-09-24 09:19AM
May-08-24 04:30PM
01:22PM
May-07-24 05:37PM
10:57AM
May-06-24 09:29AM
May-03-24 12:41PM
11:49AM
May-02-24 11:26AM
03:53AM
May-01-24 08:56PM
07:00PM
04:24PM
(Associated Press Finance)
04:10PM
04:05PM
Apr-30-24 09:50AM
Apr-24-24 04:05PM
10:01AM
05:21AM
Apr-23-24 11:15AM
Apr-17-24 04:15PM
Apr-10-24 07:45AM
Apr-04-24 09:15AM
Apr-02-24 07:30AM
Mar-29-24 11:30AM
Mar-28-24 10:15AM
Mar-20-24 10:15AM
Mar-18-24 03:28PM
Mar-17-24 08:50AM
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Henderson Mary Elizabeth SVP, Technical Operations Sep 06 '24 Sale 108.30 1,410 152,703 14,531 Sep 11 11:38 AM Henderson Mary Elizabeth Officer Sep 06 '24 Proposed Sale 110.00 2,691 296,010 Sep 05 07:50 PM Winningham Rick E Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:57 PM Smith Mark Douglas Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:55 PM RIEDEL NORBERT G Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:49 PM ORiordan Anne Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:42 PM O'Keefe Kenneth W Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:35 PM McSharry Heather Ann Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:29 PM Cook Jennifer E. Director Aug 06 '24 Proposed Sale 111.00 3,075 341,325 Aug 05 09:19 PM Sohn Catherine A. Director Aug 05 '24 Proposed Sale 111.00 3,075 341,325 Aug 02 04:20 PM Carr Patricia SVP, Chief Accounting Officer Jun 07 '24 Sale 108.83 163 17,738 6,596 Jun 11 08:15 PM Patil Neena M EVP & Chief Legal Officer May 03 '24 Sale 109.65 5,000 548,250 36,629 May 07 05:31 PM Carr Patricia SVP, Chief Accounting Officer Mar 06 '24 Sale 119.64 1,936 231,628 8,364 Mar 08 06:07 PM Carr Patricia SVP, Chief Accounting Officer Mar 07 '24 Sale 116.98 1,768 206,821 6,596 Mar 08 06:07 PM Johnson Philip L EVP & Chief Financial Officer Mar 01 '24 Buy 119.65 12,000 1,435,800 27,932 Mar 05 07:28 PM Smith Mark Douglas Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:39 PM Cook Jennifer E. Director Dec 04 '23 Sale 119.27 417 49,736 6,888 Dec 06 04:31 PM
Index RUT P/E - EPS (ttm) -2.20 Insider Own 24.24% Shs Outstand 44.45M Perf Week 1.45%
Market Cap 2.22B Forward P/E - EPS next Y -2.72 Insider Trans -1.20% Shs Float 41.54M Perf Month -13.14%
Income -107.85M PEG - EPS next Q -0.66 Inst Own 90.23% Short Float 14.86% Perf Quarter 10.12%
Sales 0.00M P/S - EPS this Y -12.53% Inst Trans 4.96% Short Ratio 11.92 Perf Half Y 1.55%
Book/sh 5.98 P/B 6.78 EPS next Y -7.30% ROA -36.41% Short Interest 6.17M Perf Year 336.71%
Cash/sh 7.01 P/C 5.79 EPS next 5Y - ROE -46.05% 52W Range 9.24 - 50.78 Perf YTD 163.78%
Dividend Est. - P/FCF - EPS past 5Y 10.22% ROI -28.49% 52W High -20.11% Beta 0.99
Dividend TTM - Quick Ratio 21.15 Sales past 5Y 0.00% Gross Margin - 52W Low 339.07% ATR (14) 2.14
Dividend Ex-Date - Current Ratio 21.15 EPS Y/Y TTM 33.79% Oper. Margin 0.00% RSI (14) 49.32 Volatility 4.09% 5.62%
Employees 51 Debt/Eq 0.16 Sales Y/Y TTM - Profit Margin - Recom 1.20 Target Price 62.60
Option/Short Yes / Yes LT Debt/Eq 0.15 EPS Q/Q -35.24% Payout - Rel Volume 0.91 Prev Close 40.71
Sales Surprise - EPS Surprise -10.71% Sales Q/Q - Earnings Aug 08 BMO Avg Volume 517.54K Price 40.57
SMA20 -1.69% SMA50 1.23% SMA200 5.19% Trades
Volume 81,802 Change -0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-16-24 Initiated Scotiabank
Sector Outperform
Jan-25-24 Initiated Oppenheimer
Outperform
$26
Jan-08-24 Initiated Cantor Fitzgerald
Overweight
Dec-18-23 Initiated Raymond James
Outperform
$29
Nov-10-23 Upgrade Jefferies
Hold → Buy
$18 → $26
Aug-16-23 Initiated Guggenheim
Buy
$27
Jan-04-23 Downgrade Wedbush
Outperform → Neutral
$33 → $8
Jan-04-23 Downgrade Jefferies
Buy → Hold
$32 → $6
Jul-12-22 Initiated JP Morgan
Overweight
$35
May-02-22 Initiated H.C. Wainwright
Buy
$35
Apr-19-22 Initiated Wedbush
Outperform
$32
Show Previous Ratings
Oct-04-24 04:05PM
Oct-02-24 06:30AM
06:30AM
Sep-26-24 03:31PM
Sep-16-24 08:00AM
08:00AM
Loading…
Sep-12-24 08:00AM
Sep-10-24 04:05PM
Sep-05-24 01:07AM
Sep-03-24 08:27AM
08:27AM
07:49AM
Sep-02-24 06:05PM
Aug-29-24 08:00AM
Aug-09-24 04:05PM
Aug-08-24 08:00AM
04:30PM
Loading…
Jul-05-24 04:30PM
Jul-01-24 08:00AM
Jun-11-24 04:01PM
Jun-07-24 04:05PM
04:05PM
May-28-24 08:00AM
May-25-24 09:40AM
May-17-24 04:27PM
May-10-24 05:38AM
May-09-24 01:53PM
08:00AM
May-07-24 04:38PM
Apr-23-24 05:09PM
(The Wall Street Journal)
Apr-13-24 05:29AM
Apr-12-24 07:01PM
04:29PM
Loading…
Apr-11-24 04:29PM
(Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM
Apr-02-24 08:00AM
Mar-20-24 12:52PM
07:30AM
Feb-28-24 04:20PM
Feb-02-24 12:40PM
08:00AM
Feb-01-24 04:05PM
Jan-29-24 11:50PM
06:15AM
Jan-25-24 06:30AM
Jan-12-24 06:44PM
Jan-08-24 08:01AM
08:00AM
Dec-27-23 08:00AM
Dec-15-23 10:15AM
Nov-14-23 05:05PM
09:55AM
Nov-09-23 09:29AM
08:00AM
Nov-04-23 10:00AM
Oct-30-23 08:00AM
Oct-18-23 09:35AM
Oct-17-23 09:35AM
Oct-16-23 09:35AM
Oct-13-23 10:22AM
Sep-26-23 04:02PM
Aug-31-23 08:00AM
Aug-16-23 10:00AM
Aug-15-23 04:03PM
Aug-10-23 08:00AM
Aug-04-23 06:30PM
Jul-24-23 09:01AM
Jul-07-23 06:35PM
Jun-27-23 08:05AM
Jun-20-23 07:04PM
09:33AM
Jun-17-23 10:10AM
Jun-15-23 04:44PM
Jun-12-23 12:05PM
Jun-11-23 01:08PM
Jun-08-23 08:00AM
Jun-07-23 08:00AM
May-11-23 08:36AM
07:30AM
May-04-23 08:00AM
Mar-28-23 07:30AM
Feb-27-23 04:05PM
Feb-14-23 07:48AM
Feb-09-23 06:51AM
05:54AM
Feb-06-23 04:05PM
Feb-01-23 09:52PM
04:01PM
Jan-30-23 07:35AM
06:00AM
Jan-25-23 08:00AM
Jan-22-23 07:39AM
Jan-06-23 05:02AM
Jan-04-23 04:07PM
(Investor's Business Daily) -64.70%
-13.31%
12:20PM
10:22AM
06:52AM
Jan-03-23 04:01PM
Dec-20-22 04:05PM
Nov-25-22 07:38AM
Nov-22-22 07:30AM
Nov-17-22 07:30AM
Nov-09-22 07:30AM
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Fordyce Marshall PRESIDENT AND CEO Oct 09 '24 Option Exercise 2.90 15,625 45,262 320,245 Oct 11 04:05 PM Fordyce Marshall PRESIDENT AND CEO Oct 09 '24 Sale 38.24 15,625 597,568 307,972 Oct 11 04:05 PM MARSHALL FORDYCE Director Oct 09 '24 Proposed Sale 38.64 15,625 603,750 Oct 09 04:17 PM Fordyce Marshall PRESIDENT AND CEO Sep 25 '24 Option Exercise 2.90 23,125 66,988 316,615 Sep 27 04:05 PM Fordyce Marshall PRESIDENT AND CEO Sep 25 '24 Sale 46.05 23,125 1,064,809 307,972 Sep 27 04:05 PM MARSHALL FORDYCE Director Sep 25 '24 Proposed Sale 46.71 7,500 350,325 Sep 25 04:21 PM SEIDENBERG BETH C Director Sep 19 '24 Sale 42.31 13,823 584,793 146,553 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.00 1,476 61,992 4,012 Sep 20 04:45 PM SEIDENBERG BETH C Director Sep 18 '24 Sale 42.01 1,177 49,448 160,376 Sep 20 04:45 PM BETH C SEIDENBERG Director Sep 18 '24 Proposed Sale 40.02 15,000 600,300 Sep 18 04:38 PM SAMUEL B SEIDENBERG IRREV TRUS Director Sep 18 '24 Proposed Sale 40.02 1,476 59,070 Sep 18 04:38 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Option Exercise 2.90 15,625 45,262 317,246 Sep 13 04:36 PM Fordyce Marshall PRESIDENT AND CEO Sep 11 '24 Sale 37.50 15,625 585,934 307,972 Sep 13 04:36 PM MARSHALL FORDYCE Director Sep 11 '24 Proposed Sale 37.55 31,250 1,173,438 Sep 11 04:19 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Option Exercise 2.90 15,625 45,262 337,592 Aug 30 04:04 PM Fordyce Marshall PRESIDENT AND CEO Aug 28 '24 Sale 36.84 30,320 1,117,140 307,972 Aug 30 04:04 PM MARSHALL FORDYCE Director Aug 28 '24 Proposed Sale 37.65 30,320 1,141,548 Aug 28 04:15 PM Fordyce Marshall PRESIDENT AND CEO Aug 21 '24 Sale 39.76 14,471 575,425 322,667 Aug 23 05:40 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Option Exercise 2.90 15,625 45,262 352,763 Aug 16 04:31 PM Fordyce Marshall PRESIDENT AND CEO Aug 14 '24 Sale 37.56 15,625 586,927 337,138 Aug 16 04:31 PM MARSHALL FORDYCE Director Aug 14 '24 Proposed Sale 37.95 15,625 592,969 Aug 14 04:24 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Option Exercise 7.87 20,651 162,523 69,357 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Option Exercise 3.94 8,221 32,387 61,392 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 16 '24 Sale 42.32 20,651 873,890 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR May 15 '24 Sale 42.27 10,186 430,546 51,206 May 17 04:21 PM Young Joseph R SVP, FINANCE, CHIEF ACCT OFFCR Apr 10 '24 Sale 40.00 5,714 228,560 53,171 Apr 12 04:02 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Option Exercise 14.87 99,828 1,484,442 166,165 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.61 99,828 3,954,516 66,337 Apr 05 09:32 PM Grant Sean CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 39.42 18,649 735,205 0 Apr 05 09:32 PM Katabi Maha Director Mar 22 '24 Sale 40.51 413,450 16,748,860 3,133,987 Mar 25 09:46 PM Katabi Maha Director Mar 25 '24 Sale 40.50 340,000 13,770,000 2,793,987 Mar 25 09:46 PM Katabi Maha Director Mar 21 '24 Sale 44.20 81,009 3,580,723 3,547,437 Mar 25 09:46 PM Katabi Maha Director Jan 30 '24 Buy 31.00 161,290 4,999,990 3,628,446 Feb 01 05:58 PM COMMODORE CAPITAL LP 10% Owner Jan 10 '24 Sale 18.00 1,050,000 18,900,000 4,400,000 Jan 12 09:55 PM Fordyce Marshall President and CEO Dec 29 '23 Option Exercise 2.87 13,516 38,854 256,877 Jan 03 04:15 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
